Survodutide - Novel Anti Obesity Drug
Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity. While GLP-1 receptor agonists have shown promise in managing obesity and associated complications, survodutide...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dr. Annil Mahajan
2025-01-01
|
| Series: | JK Science |
| Subjects: | |
| Online Access: | https://journal.jkscience.org/index.php/JK-Science/article/view/344 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527159466754048 |
|---|---|
| author | Irtiqa Ayani Rathore Sana Malik Amarjeet Singh Vishal R Tandon Annil Mahajan |
| author_facet | Irtiqa Ayani Rathore Sana Malik Amarjeet Singh Vishal R Tandon Annil Mahajan |
| author_sort | Irtiqa Ayani Rathore |
| collection | DOAJ |
| description |
Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity. While GLP-1 receptor agonists have shown promise in managing obesity and associated complications, survodutide combines GLP-1 and glucagon receptor agonism to potentially enhance weight loss and address obesity-related co-morbidities.
|
| format | Article |
| id | doaj-art-52fc3a14e9cd45e49d583e4ae8bdab6a |
| institution | Kabale University |
| issn | 0972-1177 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dr. Annil Mahajan |
| record_format | Article |
| series | JK Science |
| spelling | doaj-art-52fc3a14e9cd45e49d583e4ae8bdab6a2025-01-16T04:31:52ZengDr. Annil MahajanJK Science0972-11772025-01-01271Survodutide - Novel Anti Obesity DrugIrtiqa Ayani RathoreSana MalikAmarjeet SinghVishal R TandonAnnil Mahajan Survodutide (BI 456906) is a novel, dual agonist of glucagon and glucagon-like peptide-1 (GLP-1) receptors developed as a once-weekly subcutaneous injection for the management of obesity. While GLP-1 receptor agonists have shown promise in managing obesity and associated complications, survodutide combines GLP-1 and glucagon receptor agonism to potentially enhance weight loss and address obesity-related co-morbidities. https://journal.jkscience.org/index.php/JK-Science/article/view/344SurvodutideObesity |
| spellingShingle | Irtiqa Ayani Rathore Sana Malik Amarjeet Singh Vishal R Tandon Annil Mahajan Survodutide - Novel Anti Obesity Drug JK Science Survodutide Obesity |
| title | Survodutide - Novel Anti Obesity Drug |
| title_full | Survodutide - Novel Anti Obesity Drug |
| title_fullStr | Survodutide - Novel Anti Obesity Drug |
| title_full_unstemmed | Survodutide - Novel Anti Obesity Drug |
| title_short | Survodutide - Novel Anti Obesity Drug |
| title_sort | survodutide novel anti obesity drug |
| topic | Survodutide Obesity |
| url | https://journal.jkscience.org/index.php/JK-Science/article/view/344 |
| work_keys_str_mv | AT irtiqaayanirathore survodutidenovelantiobesitydrug AT sanamalik survodutidenovelantiobesitydrug AT amarjeetsingh survodutidenovelantiobesitydrug AT vishalrtandon survodutidenovelantiobesitydrug AT annilmahajan survodutidenovelantiobesitydrug |